Your browser doesn't support javascript.
loading
Cryopreserved amniotic membrane in the treatment of diabetic foot ulcers: a case series.
Valiente, Mónica Rodríguez; Nicolás, Francisco J; García-Hernández, Ana M; Fuente Mora, Cristina; Blanquer, Miguel; Alcaraz, Patricio J; Almansa, Sonia; Merino, Guadalupe Ruiz; Lucas, Ma Dolores López; Algueró, María C; Insausti, Carmen L; Piñero, Antonio; Moraleda, José M; Castellanos, Gregorio.
Affiliation
  • Valiente MR; Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain; and Department of General Surgery, Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical
  • Nicolás FJ; Molecular Oncology and TGFß, Research Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca).
  • García-Hernández AM; Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Fuente Mora C; Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Blanquer M; Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Alcaraz PJ; Department of General Surgery, Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Almansa S; Department of General Surgery, Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Merino GR; FFIS de la Región de Murcia, Support Research Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Lucas MDL; Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Algueró MC; Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Insausti CL; Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Piñero A; Department of General Surgery, Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Moraleda JM; Cell Therapy Unit at Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
  • Castellanos G; Department of General Surgery, Hospital Clínico Universitario Virgen de la Arrixaca. Biomedical Research Institute of Murcia (Instituto Murciano de Investigación Biosanitaria, IMIB-Arrixaca). El Palmar, Spain.
J Wound Care ; 27(12): 806-815, 2018 12 02.
Article in En | MEDLINE | ID: mdl-30557111
ABSTRACT

OBJECTIVE:

The amniotic membrane (AM) is a tissue with low immunogenity and high therapeutic potential due to its anti-inflammatory, anti-fibrotic and antimicrobial effects. This paper describes the use of cryopreserved amniotic membrane allografts to treat diabetic foot ulcers (DFUs) in patients with diabetes.

METHOD:

In this case series, AM was processed to obtain a final medicinal product cryopreserved amniotic membrane. cryopreserved AM was applied every 7-10 days until total epithelialisation of the DFUs.

RESULTS:

A total of 14 patients with DFUs (median size 12.30cm, (range 0.52-42.5cm2) were treated and followed up until complete closure (median time 20 weeks, range 7-56 weeks). Patients received 4-40 AM applications. All patients in this study achieved complete epithelialisation of the wound. No adverse events were observed.

CONCLUSION:

AM is a feasible and safe treatment in complex DFUs. Furthermore, the treatment is successful in achieving epithelialisation of long-evolution, unhealed wounds resistant to conventional therapies.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Wound Healing / Cryopreservation / Diabetic Foot / Allografts / Amnion Type of study: Observational_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Wound Care Journal subject: ENFERMAGEM Year: 2018 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Wound Healing / Cryopreservation / Diabetic Foot / Allografts / Amnion Type of study: Observational_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Wound Care Journal subject: ENFERMAGEM Year: 2018 Document type: Article